Contains Nonbinding Recommendations
4
updating the notification. Timely notification about those emerging signals based on the factors
described in this guidance document is intended to provide health care providers, patients, and
consumers with access to the most current information concerning the performance and potential
benefits and risks of marketed medical devices so that they can make informed patient
management decisions about their treatment and diagnostic options. Public notification at an
early stage may reduce or limit the number of patients exposed to the potential risk while the
issue is being further evaluated, and may promote enhanced vigilance on the part of clinicians,
risk managers, patients and consumers. This awareness may assist in the recognition of an
adverse event before more serious complications or sequelae occur.
FDA’s guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should
be viewed only as recommendations, unless specific regulatory or statutory requirements are
cited. The use of the word should in Agency guidances means that something is suggested or
recommended, but not required.
II. Background
All medical devices have benefits and risks. FDA weighs probable benefit to health from the use
of the device against any probable risk of injury or illness from such use in determining the
safety and effectiveness of a device.
3
Once FDA has made its determination, health care
providers, patients, and consumers must weigh these benefits and risks when making patient
management decisions. However, not all information regarding benefits and risks for a given
device may be known before the device reaches the market. New information about a device’s
safety and/or effectiveness, including unanticipated adverse events, may become available once
the device is more widely distributed and used under real-world conditions and in broader patient
populations than may have been studied in support of a marketing application. Also, subsequent
changes made to the device, its manufacturing process, or supply chain may lead to new safety
problems.
4
This new information may include, but is not limited to, a newly recognized type of adverse
event associated with a medical device, an increase in the severity or frequency of a known
adverse event, new product-product interactions, device malfunctions or patient injuries
potentially related to improper device use or design, or a reduction in benefit to the patient. An
emerging signal may be associated with one product from one manufacturer, one type of product
or similar products from multiple manufacturers, or multiple different product types from
multiple different manufacturers (e.g., materials issues).
FDA strives to provide current information concerning the benefits and risks of marketed
medical devices to health care providers, patients, and consumers so that they can make informed
treatment and diagnostic decisions.
5
To ensure thorough assessment of new information and the
timely communication of emerging signals, FDA’s Center for Devices and Radiological Health
3
See 21 U.S.C. 360c(a)(2) and 21 CFR 860.7.
4
Such changes may trigger the need for a new premarket submission.
5
FDA discloses such information pursuant to all applicable laws, regulations, and policies, including sections 301(j)
and 520(c) of the FD&C Act, the Trade Secrets Act, the Privacy Act, and FDA disclosure regulations.